INTENSITY THERAPEUTICS, INC. (INTS) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$3.08M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$2.53M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$2.73M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$2.71M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$3.08M | (m) | (m) | (m) | (m) | -$2.34M* | (m) | $1.83M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$2.53M | (m) | (m) | (m) | (m) | -$1.83M | (m) | $1.20M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$2.73M | (m) | (m) | (m) | (m) | -$2.39M* | (m) | $1.55M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$2.71M | (m) | (m) | (m) | (m) | -$2.46M* | (m) | $1.54M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$3.39M | (m) | (m) | (m) | (m) | -$1.99M | (m) | $2.19M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$3.57M | (m) | (m) | (m) | (m) | -$3.97M* | (m) | $2.15M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$5.07M | (m) | (m) | (m) | (m) | -$4.21M* | (m) | $3.56M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$4.74M | (m) | (m) | (m) | (m) | -$4.37M | (m) | $2.81M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$2.49M | (m) | (m) | (m) | (m) | -$5.12M* | (m) | $1.35M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$1.22M | (m) | (m) | (m) | (m) | -$239.00K* | (m) | $859.00K | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$1.25M | (m) | (m) | (m) | (m) | -$901.00K | (m) | $774.00K | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$1.77M | (m) | (m) | (m) | (m) | -$1.03M* | (m) | $1.16M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$1.93M | (m) | (m) | (m) | (m) | (m) | (m) | $1.39M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$11.97M | (m) | (m) | (m) | (m) | -$9.23M | (m) | $6.79M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$16.59M | (m) | (m) | (m) | (m) | -$15.22M | (m) | $10.50M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$8.32M | (m) | (m) | (m) | (m) | -$7.21M | (m) | $4.79M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$7.55M | (m) | (m) | (m) | (m) | -$5.48M | (m) | $5.13M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |